Variant · Amplification
NTRK1 Amplification
CI-VAR-00000229Explore in graph →CIViC 1280
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32323889
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Esophageal Carcinoma1 | ||||||||
| NTRK1 Amplification | Larotrectinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID12120A 71-year-old male with esophageal carcinoma harboring NTRK1 amplification, based on FoundationOne CDx profiling test, was treated with larotrectinib. Treatment with larotrectinib led to a shrinkage o… (full text at CIViC) PMID 32323889 · Hempel et al., 2020 · Open in CIViC | civic |
| Malignant Neoplasm1 | ||||||||
| NTRK1 Amplification OR NTRK3 Amplification OR NTRK2 Amplification | Entrectinib | Predictive | B | Does Not Support Sensitivity Response | 1 | accepted | EID2958Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. … (full text at CIViC) | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available